Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., the technology transfer arm of the University, today announced that it has signed a long-term multi-project research and license collaboration agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY).
According to the terms of the agreement, Roche has selected six promising research projects in the fields of stem cells, biomarkers, and novel molecules for the treatment of metabolic diseases, initiated by Hebrew University researchers. The expected duration of each collaborative research project is 1-3 years. Following successful completion of the different research plans, Roche shall have exclusive license to commercialize the results in consideration for the payment of transfer fees, milestone payments and royalties.
The chosen projects are: